Nanomab is guided by a highly experienced board of directors with decades of experience across the pharmaceutical and life science sectors. 

Dr. HH Ting
Dr. HH Ting Executive Chair and Chief Scientific Officer
Dr. Ting is a scientist, entrepreneur and angel investor. He has extensive experience in nuclear medicine and the Chinese healthcare sector. Most recently, he served as CEO and co-founder of Oxford Vacmedix and Biovue Technology Ltd. He was also the co-founder of Genemedix Plc., a biotechnology company once co-listed in main boards of LSE and SSE before its acquisition by the Reliance Group. Earlier in his career, he was the China General Manager of Amersham International Plc. and worked as a consultant for Westinghouse Electric, J&J and GE Healthcare. Dr. Ting received his DPhil degree from the University of Oxford, and held a permanent university senior research staff position under Professor J.E.Baldwin’s group before he left for industry.
Henry HH Ho
Henry HH HoCo-founder and Executive Director
Mr. Ho has over 30 years of operational, financial and capital market experience in industries that include healthcare & investment banking. Prior to joining NanoMab, he served as the GM of Ningbo JACO Pharmaceutical, and was responsible for its nuclear medicine product line expansion. He also served as director of Tasly Pharmaceutical Group and co-founded Oxford VacMedix. He held senior positions at various financial institutions, including Greater China head at Baring Asset Management Asia, Founder of Atlantis Investment Management Asia and China research head at Morgan Stanley, Merrill Lynch and UBS. He also had experience with publicly listed companies, including directorship at HK companies and CFO of a NASDAQ company. Mr. Ho holds a master’s degree in accounting and finance from Lancaster University, UK and is a fellow member of HKICPA.
Paul Edwards MBE
Paul Edwards MBEChief Executive Officer
Paul has 40 years’ experience in the pharmaceutical and life science arena. A graduate chemist, he initially worked for Beecham Pharmaceuticals and Genzyme Corporation, where he headed the UK operations for the company. In 2000, he joined the UK based biosimilars’ organisation, GeneMedix plc as Chief Executive Officer, and successfully led a major funding round taking the company to a dual listing on the London and Singapore Stock Exchanges. More recently, Paul has acted as a NED to Goldshield Group plc and BioProducts Laboratories and oversaw the sale of both organisations to Private Equity Groups, as well as serving as Managing Partner and board member of the global Executive Search Group, Horton International.
Paul is a familiar face in the UK biotech arena, having been the Chairman of the UK BioIndustry Association’s Manufacturing Advisory Committee and was the recipient of the Donald Medal for services to Biochemical Engineering (1999). In 1997 he received an MBE for services to biotechnology
James PoonNon-Executive Director
Mr. Poon has over 25 years of experience in the global investment banking industry with his last position as CEO of Yuanta Securities in Hong Kong. He has held various senior positions at other financial institutions including Cazenove, Smith New Court, Kleinwort Benson, UBS and CICC. During his time at the above organizations, James was deeply involved, in the capacity as a senior banker, in many landmark equity fundraisings. Since leaving the industry Mr. Poon has actively worked in the field of PE and VC investments. He has invested in over 30 deals over the last 7 years. He has a master’s degree in International Accounting & Finance from the London School of Economics and Political Science.
Ian MiscampbellNon-Executive Director
Ian has served as Chief Finance Officer and as Chief Operating Officer in a number of publicly quoted and privately owned healthcare and drug development companies, including Reneuron, KS Biomedix, Microscience, Oxford Immunotec, William Ransom and York Pharma. He was responsible for numerous M&A and licensing transactions and has completed a dozen financing and re-financing transactions, successfully raising in excess of £100m in equity, debt and grant finance. Having spent a short period working as Finance Director in a healthcare fund management business, Ian left in 2010 to establish Sixth Element Capital. Ian was appointed a Fellow of the Institute of Chartered Accountants in England and Wales in 2011.